Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Alaunos Therapeutics Stock Quote

Alaunos Therapeutics (NASDAQ: TCRT)

$1.09
(-2.7%)
-$0.03
Price as of April 22, 2024, 4:00 p.m. ET

Alaunos Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
TCRT -85.75% -98.25% -55.49% -98%
S&P +20.28% +70.99% +11.31% +312%

Alaunos Therapeutics Company Info

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

News & Analysis

The Fool has written over 100 articles on Alaunos Therapeutics.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.